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Background: The efficacy and safety of preoperative chemoradiation therapy (CRT) for advanced esophago-gastric
adenocarcinoma are still in question, and the prognosis of these patients is poor.
Methods: We systematically searched electronic databases from January 1990 to July 2014. The primary outcome was
overall survival. The secondary outcomes were a R0 resection rate, positive rate of lymph node metastasis, postoperative
recurrence rate, pathological complete response (pCR) rate and perioperative mortality. Overall survival was
measured with a hazard ratio (HR), while other secondary outcomes were measured with an odds ratio (OR).
Results: Seven randomized controlled trials (RCTs) including 1085 patients were searched and, of these, 869 had
adenocarcinoma. Patients receiving preoperative CRT had a longer overall survival (HR 0.74; 95% confidence interval
(CI) 0.63–0.88), higher likelihood of R0 resection and greater chance of pCR, while they had a lower likelihood of
lymph node metastasis and postoperative recurrence. The difference of perioperative mortality was non-significant. In
addition, the result of the comparison between preoperative CRT and preoperative chemotherapy (CT) in two RCTs
was non-significant.
Conclusion: Patients with resectable esophago-gastric adenocarcinoma can gain a survival advantage from preoperative
CRT. However, limited to the number of RCTs, the effect of adding radiotherapy to preoperative CT separately is
still uncertain and more high-quality prospective trials are needed.
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Meta-analysisBackground
Throughout the world, adenocarcinoma of the esophagus,
gastroesophageal junction and stomach rank among the
most common cancers [1-3]. Additionally, during the past
decade, there has been a dramatic increase in the inci-
dence of gastro-esophageal junction cancer [4]. Adenocar-
cinoma accounts for a great majority of the cases of
gastro-esophageal junction carcinoma in East Asia [5,6].
Furthermore, the prognosis of patients with these types of
cancer is bleak [7,8]. Generally, surgery is the primary
intervention for local advanced gastro-esophageal ade-
nocarcinoma. However, the overall survival rates with* Correspondence: jijiafu_pku@163.com
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unless otherwise stated.surgery alone remain low, while the recurrence rates re-
main stubbornly high in most series [9]. The poor survival
rates provide a strong rationale for the design of new
treatment modalities.
As early as 1896, X-ray was first used in tumor therapy
by Despeignes [10]. More than a century later, our un-
derstanding and development of radiotherapy led to a
significant role in the comprehensive treatment of
gastro-esophageal cancer. As patients can benefit from
radiotherapy on a local control ratio, clinical experts can
apply preoperative tumor down-staging and improve the
resection rates of carcinoma. In addition, compared with
postoperative radiotherapy, preoperative therapy is more
accurate for the localization of the tumor [11]. However,
as it is recognized as a systemic disease, patients withis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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therapy as early as possible. If chemotherapy precedes
preoperative radiotherapy alone, considering the interval
between radiotherapy and surgery and the possible com-
plications after surgery, the initial time of systemic
chemotherapy will be further delayed. According to the
sensitization of chemotherapy [12], Several phase II
studies and RCTs have found that preoperative CRT has
preferable safety and efficacy for local advanced gastro-
esophageal adenocarcinoma [11,13-18].
Although some RCTs have proven the effectiveness of
neoadjuvant chemoradiation therapy, there is the con-
cern that meta-analysis would provide more powerful
evidence for clinical decision-making relative to RCTs.
However, the latest meta-analysis regarding preoperative
CRT for gastro-esophageal carcinoma was published on
2007 [19], and the article only contains 3 RCTs that
range from 1989 to 2006, while there were 4 new RCTs
published from 2007 to 2014. Furthermore, the previous
meta-analyses mainly focused on all types of gastro-
esophageal carcinoma and contained not only preopera-
tive CRTs but also preoperative chemotherapy [20,21],




To identify useful studies and published abstracts,we sys-
tematically searched electronic databases including the
Cochrane Central Register of Controlled Trials (CEN-
TRAL), PubMed, Excerpta Medica Database (EMBASE),
the Cochrane Database of Systematic Reviews and the
China National Knowledge Infrastructure (CNKI). There
were no language restrictions. The medical subject head-
ings were listed as follows: esophagus/gastroesophageal
/gastric adenocarcinoma, preoperative chemoradiation
therapy, and randomized controlled trials (RCT). The
search included literature published from January 1990 to
July 2014. We also reviewed all abstracts that were poten-
tially relevant to our subject. Furthermore, other grey lit-
erature as well as unpublished work, ongoing studies and
negative results were searched as well. Two investigators
conducted the search independently, and their results
were combined.
Study review and inclusion
Two authors independently reviewed the study. The titles
and abstracts were in agreement with the articles to be re-
trieved. To identify studies for the analysis, the inclusion
criteria were designed as follows: (1) published RCTs that
had a clear statement in the Materials and Methods section.
(2) RCTs comparing preoperative CRT plus surgery with
surgery alone or preoperative CRT plus surgery with pre-
operative chemotherapy plus surgery. (3) RCTs includingpatients with resectable, histologically proven adenocar-
cinoma of the esophagus, stomach or gastroesophageal
junction without metastatic disease. (4) RCTs with a
low risk of selection bias, performance bias, detection
bias, attrition bias, reporting bias and other bias. Bias
was assessed using Begg’s and Egger’s tests [22,23]. (5)
Patient survival was used as the measureable outcome.
Outcome measures
The primary outcome was overall survival, mostly based
on an intention-to-treat analysis. The secondary out-
comes were the R0 resection rate, which was defined by
a tumor-free resection margin; positive rate of lymph
node metastasis; postoperative recurrence rate; complete
pathological response rate; and perioperative mortality.
Statistical analyses
Data analysis was performed using Review Manager 5.2.0
for Windows. Overall, survival was measured with a haz-
ard ratio (HR), while the R0 resection rate, positive rate of
lymph node metastasis, postoperative recurrence rate and
perioperative mortality were measured using odds ratios
(OR). Furthermore, intention-to-treat (ITT) analyses were
conducted when possible. If permitted, HR and the corre-
sponding standard errors were obtained directly from the
article; otherwise, they were calculated using the methods
of Parmar [24], Tierney [25], and Williamson [26]. These
approaches use confidence intervals, log-rank p-values,
number of events and Kaplan–Meier survival curves to es-
timate the HR and standard errors. Moreover, the mea-
sures of HR and OR were investigated for statistical
heterogeneity by I2 statistics, with a value of I2 > 50% indi-
cating substantial heterogeneity. Where there was evi-
dence of heterogeneity, subgroup analysis or sensitivity
analysis were performed to investigate possible bias and
derived summary estimates according to the random ef-
fect model; otherwise, the Mantel-Haenszel fixed effect
model was used to compute the results. All of the signifi-
cance tests were two-sided, with p = 0.05 as the cutoff.
Results
Identification of studies and features of the RCTs
The results of the literature search are displayed in a Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) diagram (Figure 1). A total of 1522
studies were retrieved in the database, and 4 additional
studies were found from other channels, such as confer-
ence reports, and so on. Among them, 1519 records were
mostly unrelated to our subject, and only 7 RCTs met our
inclusion criteria, which examined a total of 1085 patients.
The main features of the trials included in the meta-
analysis are shown in Table 1. The seven RCTs included
869 patients with esophago-gastric adenocarcinoma, 430
of whom received CRT before surgery. Approximately 5
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram. The figure displays the information retrieval
process for valuable articles and indicates the exclusion process of irrelative articles for this research.
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therapy (CRT) followed by surgery versus surgery alone
[27-31], while 2 RCTs focused on the topic of CRT
followed by surgery versus preoperative chemotherapy
(CT) followed by surgery [32,33]. The cancer positions in-
volved in the 6 RCTs were of the esophagus and gastro-
esophageal junction, and 2 RCTs referred to the cardia. In
addition, the median age of patients ranged from 56 to
65 year, and the proportion of females was 18.4%. Table 2
and Table 3 display some other characteristics regardingTable 1 Basic characteristics of the randomized controlled tri























Note: pCR: pathological complete response; CRT: preoperative chemoradiation therathe RCTs included in our study. The total sample size of
our meta-analysis was 1085, which contained 869 patients
with adenocarcinoma, while the number of each RCTs
varied greatly. The 3 year and 5 year overall survival (OS)
rate are also displayed in Tables 2 and 3, where there was
a certain difference between the CRT plus surgery group
and the surgery alone or CT plus surgery groups. The
treatment schedule is also listed (Tables 2 and 3). Add-
itionally, no publication bias was found from the funnel
plots (Figure 2).als included
section Down-staging pCR of CRT Journal publication
13(25.0%) NEJM
8%) 9(24.3%) JCO





py; CT: preoperative chemotherapy; NM: not mentioned.
Table 2 Preoperative CRT versus surgery alone
Study and year Sample size Treatment approach Treatment schedule (CRT) 3 y or 5 y OS (CRT V. Surg)
Walsh, [27] 113 CRT-Surgery V. Surgery
40Gy/15f/15d 3y: 32% V. 6%
5-Fu (15 mg/kg/d)
5y: NM
Cisplatin (75 mg /m2)
Urba, [30] 100 CRT-Surgery V. Surgery




TROG, [31] 256 CRT-Surgery V. Surgery
35Gy/15f/3w 3y: 25.6% V. 24.1%
Cisplatin (80 mg/m2)
5y: 11.5% V. 9.6%
5-Fu (800 mg/m2)
CALGB9781, [28] 56 CRT-Surgery V. Surgery
50.4Gy/28f/28d 3y: NM
Cisplatin (100 mg/m2)
5y: 39% V. 16%
5-Fu (1000 mg/m2/d)
CROSS, [29] 366 CRT-Surgery V. Surgery
41.4Gy/23f 5f/w 3y: 39.6% V. 35.5%
Carboplatin (2 mg/ml/min)
5y: 13.4% V. 7.1%
Paclitaxel (50 mg/m2)
Note: OS: overall survival; CRT: preoperative chemoradiation therapy; CT: preoperative chemotherapy; V: versus; Surg: surgery; 5-Fu: fluorouracil; NM: not mentioned.
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The primary outcome examined in our study was overall
survival and was reported in all seven RCTs. The meta-
analysis gave the result that the pooled HR was 0.74
(95% CI 0.63–0.88) for the preoperative CRT plus sur-
gery group compared to the preoperative CT plus sur-
gery or surgery alone groups (Figure 3). It is noteworthy
that four RCTs not only contained adenocarcinoma but
also contained squamous cell carcinoma (SCC) [28-31].
Therefore, the individual HR of the CROSS trial and the
TROG trial, excluding SCC, were calculated separately
from the data given by the original article, and the re-
sults were 0.73 (95% CI 0.54-1.00) in the CROSS trial
and 1.02 (95% CI 0.72-1.44) in the TROG trial. In the
CALGB9781 trial and Urba’s trial, the individual data of
SCC were not displayed; however, the number of SCC in
these two studies was only 37. Compared to the total
number of 869, the interference of these 37 SCC patients
could be ignored. As the heterogeneity test was notTable 3 Preoperative CRT versus preoperative CT
Study and year Sample size Treatment approach Treatm










Note: OS: overall survival; CRT: preoperative chemoradiation therapy; CT: preoperati
not mentioned.statistically significant (I2 = 13%), the fixed effect model
was used to calculate the result for OS. Figure 3 shows
Forest plots for OS. The individual HR ranged from 0.45
(95% CI 0.20-1.01) for the CALGB9781 trial to 1.02
(95% CI 0.72-1.44) for the TROG trial; only a single indi-
vidual HR favored the preoperative CRT group. This re-
sult together with those of the pooled HR indicated that
there was a survival advantage for patients with pre-
operative CRT followed by surgery. In addition, accord-
ing to the results of the heterogeneity test, there was no
need to perform sensitivity analysis or subgroup analysis
for the primary outcome.
Secondary outcomes
Figure 4, 5, 6, 7 show Forest plots for the secondary out-
comes, including the R0 resection rate, positive rate of
lymph node metastasis, postoperative recurrence rate,
pathological complete response rate (pCR) and peri-
operative mortality. Five RCTs reported the R0 resectionent schedule 3 y or 5 y OS (CRT V. CT + S)
e of CRT: GTV30Gy/15f cisplatin
g/m2), etoposide (80 mg/m2)
3y: 52% V. 49%
e of CT: 5-Fu (2 g/m2) leucovorin
g/m2) cisplatin (50 mg/m2)
5y: 45% V. 36%
e of CRT: Cisplatin (80 mg/m2) 5-Fu
mg/m2/d) GTV35Gy/15f
3y: 47.4% V. 27.7%
5y: NMe of CT: Cisplatin(80 mg/m2) 5-Fu
mg/m2/d)
ve chemotherapy; V: versus; Surg: surgery; 5-Fu: fluorouracil; NM:
Figure 2 Funnel plots for the primary outcome. The horizontal axis corresponds to the study-specific HR which means the efficacy of the therapy.
The vertical axis corresponds to the study-specific SE which means the size of the study. The circles represent the study included. The area of the
dash line represents the range without bias in the study.
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2.35, 95% CI 1.29–4.30, Figure 3). As the heterogeneity
test was statistically significant (I2 = 59%), random effect
modeling and subgroup analysis were performed, reveal-
ing a significant difference in the comparison between
preoperative CRT and surgery alone (OR 3.55, 95% CI
2.34–5.39), while no statistically significant difference
was observed in the comparison between preoperative
CRT and preoperative CT (OR 1.17, 95% CI 0.61–2.27).
Five RCTs reported a postoperative recurrence rate that
included local and distant failure, indicating a statisti-
cally significant difference (OR 0.51, 95% CI 0.38–0.68,
Figure 2), and no statistical heterogeneity was detected
(I2 = 0%). Five RCTs reported the positive rate of lymph
node metastasis according to the postoperative patho-
logical report. The pooled OR was 0.30 (95% CI 0.23-
0.39), revealing a significant difference, and no statistical
heterogeneity was detected (I2 = 49%). Five RCTs reportedFigure 3 Forest plots for the primary outcome overall survival. The squares
The area of the squares reflects the study-specific weight. The diamond repperioperative mortality, and there was no statistically
significant difference between the two groups (OR 1.10,
95% CI 0.62–1.93, Figure 4) nor a statistical heterogeneity
(I2 = 0%). Six RCTs reported pCR after chemoradiation
therapy, while two trials revealed pCR after chemotherapy,
and the result of pCR in the chemoradiation therapy
group was 21.56% (Table 1).
Discussion
Preoperative CRT has been used in the comprehensive
treatment of GEJ and esophagus cancers for decades and
has shown good curative effects in local control and pro-
longed overall survival. As early as 1978, Zhang had
already carried out an elementary trial about preopera-
tive CRT that confirmed that CRT was able to improve
the results of surgery for GEJ cancer [34]. In the thirty
years since, oncologists have put significant effort into
the research of preoperative CRT and have had someand horizontal lines correspond to the study-specific HR and 95% CIs.
resents the pooled HR and 95% CI.
Figure 4 Forest plots for the secondary outcome the R0 resection rate by different control groups. The squares and horizontal lines correspond
to the study-specific HR and 95% CIs. The area of the squares reflects the study-specific weight. The diamond represents the pooled HR and
95% CI.
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study proved that preoperative CRT was well tolerated
and comparable to similarly staged, adjuvantly treated pa-
tients [35]. In Europe, a Spanish phase II study indicated
that preoperative CRT showed an acceptable toxicity and
promising activity [17], while a Polish phase II study re-
vealed that CRT was effective and showed a good toxicity
profile [18]. In Asia, a Japanese phase I study indicated
that CRT might cause surgery to be delayed, but showed
promise for resectable advanced gastric cancer, while a
Korean phase I study showed that CRT could be explored
more extensively [36]. Although all of these studies indi-
cated a tendency for preoperative CRT to obtain more
powerful evidence, this meta-analysis was conducted to
evaluate preoperative CRT for patients with resectable
esophago-gastric adenocarcinoma.Figure 5 Forest plots for the secondary outcome positive rate of lymph no
study-specific HR and 95% CIs. The area of the squares reflects the study-spThis meta-analysis is based on 7 RCTs published from
1996 to 2012. The most important achievement of this
study is the result that patients with resectable esophago-
gastric adenocarcinoma tended to have a survival advan-
tage from preoperative CRT compared with surgery alone
or preoperative CT followed by surgery. Although most of
the individual HRs indicated no significant difference, the
pooled HR revealed favorable results for the CRT group.
The 3-year OS of Walsh’s study in the CRT and surgery
group was 32% and 6%, while the median survival time
was 16 months and 11 months (p < 0.01). Some individual
data, such as the results above, indicated this opinion as
well.
To identify the effect of adding radiotherapy to pre-
operative CT separately, we focused on the five RCTs
that compared the survival benefit between preoperativede metastasis. The squares and horizontal lines correspond to the
ecific weight. The diamond represents the pooled HR and 95% CI.
Figure 6 Forest plots for the secondary outcome postoperative recurrence rate. The squares and horizontal lines correspond to the study-specific
HR and 95% CIs. The area of the squares reflects the study-specific weight. The diamond represents the pooled HR and 95% CI.
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CI 0.62-0.90), which revealed a significant difference
between these two groups. On the other hand, the re-
sults of the comparison between preoperative CRT and
preoperative CT in the remaining two RCTs were disap-
pointing because the pooled HR was 0.71 (95% CI 0.48-
1.05), which compared with preoperative CT meant that
patients may receive a benefit from preoperative CRT,
but the effect was not significant. This result was con-
sistent with the conclusion of another meta-analysis
published previously [20]. We arrived at the deduction
that preoperative CRT as a whole could bring a survival
advantage for patients with esophago-gastric adenocar-
cinoma; however, limited to the number of RCTs that
compared the effect between preoperative CRT and CT,
we were not able to confirm the effect of radiotherapy
separately. Perhaps there was a potential difference be-
tween preoperative CRT and CT; however, this differ-
ence was not observed due to the restricted number of
RCTs. Therefore, the true benefit of radiotherapy separ-
ately might be much greater, and efforts to enlarge the
simple size to prove the supposition are warranted.
To determine the reason that patients with resectable
esophago-gastric adenocarcinoma could receive a sur-
vival advantage from preoperative CRT, we chose the R0
resection rate, positive rate of lymph node metastasis,Figure 7 Forest plots for the secondary outcome perioperative mortality. T
and 95% CIs. The area of the squares reflects the study-specific weight. Thepostoperative recurrence rate and pathological complete
response rate as secondary outcomes. The final results
revealed that the pooled ORs of the R0 resection rate,
positive rate of lymph node metastasis and postoperative
recurrence rate favored the group of preoperative CRT.
Furthermore, the combined pCR rate of six RCTs was
21.56%, which approximated the results of other studies
[19,37,38]. According to the data above, downstaging as
a result of preoperative CRT was reflected in the signifi-
cantly higher percentage of the negative rate of lymph
node metastasis and pCR rate. Therefore, our analyses
concluded that downstaging, the possibility of complete
resection and the decreased likelihood of local recur-
rence as a local control rate, which were the mecha-
nisms of preoperative CRT, prolong survival. In addition,
the pooled ORs of the R0 resection rate (OR 1.17, 95%
CI 0.61-2.27) and postoperative recurrence rate (OR
0.57, 95% CI 0.32-1.02) were both non-significant, while
only the pooled OR of the positive rate of lymph node
metastasis (OR 0.40, 95% CI 0.22-0.72) was significant.
This result also proved the conclusion above that com-
pared with preoperative CT group; the local control rate
responsible for the survival benefit was provided with a
rising trend in the preoperative CRT group. However,
further RCTs were necessary. Moreover, our analyses
found that the pooled OR of perioperative mortality (ORhe squares and horizontal lines correspond to the study-specific HR
diamond represents the pooled HR and 95% CI.
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meant that preoperative CRT was safe and tolerable.
There were some other valuable studies that compared
the effects of preoperative CRT and surgery alone in pa-
tients with resectable esophago-gastric adenocarcinoma
that were not included in this meta-analysis. The
FFCD9901 trial focused on the survival outcomes for pa-
tients with localized (stages I or II) resectable esophageal
carcinomas [39]; however, it is regrettable that the sur-
vival result was non-significant. We excluded this article
because 75% of the patients suffered from squamous cell
carcinoma and two thirds of the tumors were node-
negative, which might be the cause of the negative re-
sults. Furthermore, a phase II study released on the 2013
ESMO meeting that took a therapeutic regimen as indu-
cing chemotherapy followed by concurrent CRT before
surgery reached a favorable result. The downstaging rate
was 67%, while the pCR rate was 18%. This study mainly
focused on the gastric adenocarcinoma and involved tu-
mors on the antrum of the stomach. As its special value,
a larger randomized trial is expected. From the clinical
trial database, we also found an ongoing RCT from
Australia that compared the survival differences between
preoperative CRT and CT. Patients with adenocarcin-
oma of the stomach or gastroesophageal junction were
included. It remains to be seen whether the final result
will be favorable.
Conclusion
All of the studies included in our meta-analysis are
RCTs, and we were fortunate to reach a significant result
with slight heterogeneity, which was resolved by sub-
group analyses. Therefore, our meta-analysis demon-
strates that patients with resectable esophago-gastric
adenocarcinoma can gain a survival advantage from pre-
operative CRT. However, due to the limitations of the
number of RCTs, the benefit of adding radiotherapy to
preoperative CT separately is still uncertain and add-
itional high-quality prospective trials are needed.
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